DLA Piper advises Symphar on sale to pharmaceutical manufacturer Farmak

DLA Piper has advised the shareholders of Symphar sp. z o.o., a leading Polish pharmaceutical business, on the sale of 100% of share to Farmak, a global manufacturer of pharmaceutical products. Symphar’s acquisition will expand Farmak’s market share in the CEE region.

A leading pharmaceutical company, Symphar has over 90 employees and is engaged in the development and manufacture of more than 50 products in diabetology, gynecology, psychiatry, and neurology. An active player in Poland’s pharmaceuticals market for 20 years, Symphar generated over EUR22 million of revenue in 2023.

Farmak is an international pharmaceutical company with manufacturing and R&D facilities in Ukraine and Spain, with offices in Ukraine, Poland, the Czech Republic, Slovakia, Western Europe, Central Asia, the Asia Pacific region, and the Middle East.

A team from DLA Piper’s Warsaw and London offices worked on the transaction and comprised of partners Marta Frąckowiak, Piero Carbone (both Corporate), and Agnieszka Lechman-Filipiak (Employment), senior associate Michał Bałdowski, counsel Izabela Gebal, and junior associate Natalia Cichocka.